Literature DB >> 22091596

Pathways towards an effective immunotherapy for Parkinson's disease.

Jessica A L Hutter-Saunders1, Rodney Lee Mosley, Howard E Gendelman.   

Abstract

Immunizations that target specific types of immune responses are used commonly to prevent microbial infections. However, a range of immune responses may prove necessary to combat the ravages of neurodegenerative diseases. The goal is to eliminate the 'root' cause of neurodegenerative disorders, misfolded aggregated proteins, while harnessing adaptive immune responses to promote neural repair. However, immunization strategies used to elicit humoral immune responses against aberrant brain proteins have yielded mixed success. While specific proteins can be cleared, the failures in halting disease progression revolve, in measure, around adaptive immune responses that promote autoreactive T cells and, as such, induce a meningoencephalitis, accelerating neurodegeneration. Thus, alternative approaches for protein clearance and neural repair are desired. To this end, our laboratories have sought to transform autoreactive adaptive immune responses into regulatory neuroprotective cells in Parkinson's disease. In this context, induction of immune responses against modified brain proteins serves to break immunological tolerance, while eliciting adaptive immunity to facilitate neuronal repair. How to harness the immune response in the setting of Parkinson's disease requires a thorough understanding of the role of immunity in human disease and the ways to modify such immune responses to elicit therapeutic gain. These are discussed in this review.

Entities:  

Mesh:

Year:  2011        PMID: 22091596      PMCID: PMC3263336          DOI: 10.1586/ern.11.163

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  183 in total

Review 1.  Thymic generation and selection of CD25+CD4+ regulatory T cells: implications of their broad repertoire and high self-reactivity for the maintenance of immunological self-tolerance.

Authors:  Shimon Sakaguchi; Shohei Hori; Yoshinori Fukui; Takehiko Sasazuki; Noriko Sakaguchi; Takeshi Takahashi
Journal:  Novartis Found Symp       Date:  2003

2.  Alterations of T-lymphocyte populations in Parkinson disease.

Authors:  Yasuhiko Baba; Ataru Kuroiwa; Ryan J Uitti; Zbigniew K Wszolek; Tatsuo Yamada
Journal:  Parkinsonism Relat Disord       Date:  2005-09-09       Impact factor: 4.891

3.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

4.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Authors:  D Blum-Degen; T Müller; W Kuhn; M Gerlach; H Przuntek; P Riederer
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

5.  Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system.

Authors:  Jonathan Kipnis; Tal Mizrahi; Ehud Hauben; Iftach Shaked; Ethan Shevach; Michal Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

6.  Microglial activation and chronic neurodegeneration.

Authors:  Melinda E Lull; Michelle L Block
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

7.  Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.

Authors:  Rina Aharoni; Raya Eilam; Ariel Stock; Anya Vainshtein; Elias Shezen; Hilah Gal; Nir Friedman; Ruth Arnon
Journal:  J Neuroimmunol       Date:  2010-08-25       Impact factor: 3.478

Review 8.  Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.

Authors:  Imrich Blasko; Beatrix Grubeck-Loebenstein
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Dosing in phase II trial of Alzheimer's vaccine suspended.

Authors:  Kathryn Senior
Journal:  Lancet Neurol       Date:  2002-05       Impact factor: 44.182

10.  Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function.

Authors:  S Elkabes; E M DiCicco-Bloom; I B Black
Journal:  J Neurosci       Date:  1996-04-15       Impact factor: 6.167

View more
  10 in total

Review 1.  Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?

Authors:  Marina Romero-Ramos; Marianne von Euler Chelpin; Vanesa Sanchez-Guajardo
Journal:  Hum Vaccin Immunother       Date:  2014-03-26       Impact factor: 3.452

Review 2.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 3.  A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders.

Authors:  Howard E Gendelman; R Lee Mosley
Journal:  J Neuroimmune Pharmacol       Date:  2015-10-31       Impact factor: 4.147

4.  Immunity and inflammation in neurodegenerative diseases.

Authors:  Giuseppe Cappellano; Miryam Carecchio; Thomas Fleetwood; Luca Magistrelli; Roberto Cantello; Umberto Dianzani; Cristoforo Comi
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

5.  Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.

Authors:  Md Shahaduzzaman; Kevin Nash; Charles Hudson; Masroor Sharif; Bethany Grimmig; Xiaoyang Lin; Ge Bai; Hui Liu; Kenneth E Ugen; Chuanhai Cao; Paula C Bickford
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

6.  A Novel Immunosuppressor, (5R)-5-Hydroxytriptolide, Alleviates Movement Disorder and Neuroinflammation in a 6-OHDA Hemiparkinsonian Rat Model.

Authors:  Ruijun Su; Min Sun; Wei Wang; Jianliang Zhang; Li Zhang; Junli Zhen; Yanjing Qian; Yan Zheng; Xiaomin Wang
Journal:  Aging Dis       Date:  2017-02-01       Impact factor: 6.745

7.  Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.

Authors:  Camille B Carroll; Richard K H Wyse
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

8.  First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.

Authors:  Dale B Schenk; Martin Koller; Daniel K Ness; Sue G Griffith; Michael Grundman; Wagner Zago; Jay Soto; George Atiee; Susanne Ostrowitzki; Gene G Kinney
Journal:  Mov Disord       Date:  2016-11-25       Impact factor: 10.338

9.  Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease.

Authors:  Natasa Kustrimovic; Emanuela Rasini; Massimiliano Legnaro; Raffaella Bombelli; Iva Aleksic; Fabio Blandini; Cristoforo Comi; Marco Mauri; Brigida Minafra; Giulio Riboldazzi; Vanesa Sanchez-Guajardo; Franca Marino; Marco Cosentino
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

Review 10.  Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets.

Authors:  Somin Kwon; Michiyo Iba; Changyoun Kim; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.